Two studies led by The University of Texas MD Anderson Cancer Center that shed new light on the potential of the gut microbiome as a targetable biomarker to improve responses to immunotherapy were presented today at the 2022 American Society for Clinical Oncology (ASCO) Annual Meeting.
- Detection and analysis of lung microbiota in mice with lung cancer lacking the NLRP3 gene
- Special Issue “Microbiome in Cancer: Role in Carcinogenesis and Impact in Therapeutic Strategies”
- Microbiota contributions
- Gastric Microbiome Alterations Are Associated with Decreased CD8+ Tissue-Resident Memory T Cells in the Tumor Microenvironment of Gastric Cancer
- The microbiome and human cancer